Cicletanine
As of the edition of 20 October 2026, Cicletanine is a small molecule: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Servier
- Registered trials
- 2, 1 stopped early
- Disease areas
- Heart and blood vessels; Hormones; Lungs and airways; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 0 | 0 | 1 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Lead sponsor of trials | 2009 to now |
| Navitas Pharma | Lead sponsor of trials | 2022 to now |